Venetoclax and Decitabine in R/R T-ALL

Sponsor
Seoul National University Hospital
Study ID
NCT06712121
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • T Lymphoblastic Leukemia/Lymphoma

Eligibility Criteria

Sex
ALL
Age
19 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. This study use a modified regimen of decitabine and venetoclax.

Key Dates

Start date
Jan 30, 2025
Status verified
Jan 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2028

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: decitabine and venetoclax arm
    arm treated with venetoclax plus decitabine

Primary Outcome Measure

The rate of composite Complete remission [ Time Frame: 1 year ]

Central Contacts